SCHEMBL1108967

SCHEMBL1108967

Cc1cccc(CCC(C)C)c1C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
BID P55957 4/20 0.42
MCL1 Q07820 4/20 0.42
BCL2L1 Q07817 3/20 0.42
BAK1 Q16611 3/20 0.42
KAT8 Q9H7Z6 2/20 0.42
PPARA Q07869 2/20 0.42
PPARG P37231 1/20 0.42
EP300 Q09472 1/20 0.42
KAT2A Q92830 1/20 0.42
KAT2B Q92831 1/20 0.42
KAT5 Q92993 1/20 0.42
SAE1 Q9UBE0 1/20 0.42
FOLH1 Q04609 2/20 0.40
GABRA1 P14867 1/20 0.39
GABRB2 P47870 1/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
SLC6A3 Q01959 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9338483 0.83 FOLH1 (0.49) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL5164770 0.81 BID (0.53) L3MBTL1TDP1BIDMCL1BCL2L1
SCHEMBL30179912 0.79 FOLH1 (0.40) L3MBTL1TDP1BIDMCL1BCL2L1
SCHEMBL5693066 0.79 L3MBTL1 (0.47) L3MBTL1TDP1BIDMCL1BCL2L1
SCHEMBL424866 0.78 L3MBTL1 (0.50) L3MBTL1TDP1BIDMCL1BCL2L1
SCHEMBL14312370 0.78 BID (0.54) L3MBTL1TDP1BIDMCL1BCL2L1
SCHEMBL20109916 0.77 FABP3 (0.54) L3MBTL1TDP1BIDMCL1BCL2L1
SCHEMBL623350 0.77 L3MBTL1 (0.49) L3MBTL1TDP1BIDMCL1BCL2L1
SCHEMBL9342117 0.77 BID (0.69) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL26679326 0.77 BID (0.49) BIDMCL1BCL2L1BAK1KAT8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153385-B2 Target protein and target gene in drug designing and screening method REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) 2012-04-10 US disclosed
US-20100136524-A1 TARGET PROTEIN AND TARGET GENE IN DRUG DESIGNING AND SCREENING METHOD REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136524-A1 TARGET PROTEIN AND TARGET GENE IN DRUG DESIGNING AND SCREENING METHOD CHP1, CMA1, CARHSP1 L3MBTL1 2878/4885TDP1 3414/4885BID 4415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.